Headlands Technologies LLC Grows Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Headlands Technologies LLC grew its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 183.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,432 shares of the company’s stock after acquiring an additional 20,984 shares during the quarter. Headlands Technologies LLC’s holdings in Vir Biotechnology were worth $238,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of VIR. Geode Capital Management LLC raised its stake in shares of Vir Biotechnology by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock valued at $16,127,000 after acquiring an additional 7,827 shares during the period. Artisan Partners Limited Partnership purchased a new position in Vir Biotechnology in the fourth quarter valued at about $6,742,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Vir Biotechnology by 36.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 35,081 shares of the company’s stock worth $263,000 after purchasing an additional 9,311 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Vir Biotechnology in the fourth quarter worth about $364,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Vir Biotechnology in the fourth quarter worth about $119,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Ratings Changes

VIR has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, February 28th. Barclays upped their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Leerink Partners boosted their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $35.67.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $5.58 on Friday. The company’s 50-day simple moving average is $8.36 and its 200-day simple moving average is $8.29. Vir Biotechnology, Inc. has a one year low of $5.49 and a one year high of $14.45. The stock has a market capitalization of $765.26 million, a price-to-earnings ratio of -1.42 and a beta of 1.14.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. As a group, research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the transaction, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. The trade was a 9.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,571 shares of company stock valued at $800,744 in the last quarter. Corporate insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).